<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244464</url>
  </required_header>
  <id_info>
    <org_study_id>IPV29</org_study_id>
    <secondary_id>UTN: U1111-1114-3719</secondary_id>
    <nct_id>NCT01244464</nct_id>
  </id_info>
  <brief_title>A Study of the Safety of IMOVAX Polio™ in China</brief_title>
  <official_title>Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to obtain post-marketing safety data on IMOVAX Polio™ vaccine in
      China.

      Primary Objective: To describe the safety profile after each dose of IMOVAX Polio™
      administered at 2, 3, and 4 months of age in population aged over 2 months old living in the
      study city China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive a single dose of IMOVAX Polio™ vaccine at 2, 3, and 4 months
      of age, respectively. Each participant will make a total of 7 visits. Safety will be
      monitored at each visit and up to 30 days after each vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence, duration, and relationship to vaccination of solicited and unsolicited (spontaneously reported) adverse events occurring after IMOVAX Polio™ vaccination.</measure>
    <time_frame>Day 0 to Day 30 post-vaccination</time_frame>
    <description>Solicited injection site reactions: tenderness, erythema, and swelling. Solicited systemic reactions: Fever (temperature), vomiting, abnormal crying, drowsiness, loss of appetite, and irritability.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Poliomyelitis</condition>
  <condition>Polio</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine</intervention_name>
    <description>0.5 mL, at 2, 3, and 4 months; Intramuscular</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>IMOVAX POLIO™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Subject is more than 2 months (60-89 days) old when receiving the first dose of polio
             vaccine.

          -  Subject's parents/legal representative showed willingness to complete the 3 primary
             doses fully using IMOVAX Polio™ according to the schedule: one injection at 2, 3, 4
             months old, respectively.

          -  Informed consent form obtained from the subject's parent/legal representative.

          -  Subject plan to live in the selected study sites for at least three months after
             inclusion.

        Exclusion Criteria :

          -  Subject with a history of serious illness (e.g., hypersensitivity, seizure,
             convulsion, encephalopathy diseases)

          -  Known or suspected impairment of immunologic function

          -  Acute medical illness with or without fever within the last 72 hours

          -  Subject plan to leave the study sites for at least three months after inclusion

          -  Administration of immune globulin or other blood products within the last three months

          -  Participation in another clinical trial at the same time

          -  Contraindication to vaccination according to IMOVAX Polio™ leaflet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur China</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>August 2, 2012</last_update_submitted>
  <last_update_submitted_qc>August 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Poliomyelitis</keyword>
  <keyword>IMOVAX POLIO™</keyword>
  <keyword>Polio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

